Net Cash Provided by (Used in) Financing Activities of NEKTAR THERAPEUTICS from 31 Mar 2010 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
NEKTAR THERAPEUTICS annual and quarterly Net Cash Provided by (Used in) Financing Activities in USD history and change rate from 31 Mar 2010 to 31 Dec 2025.
  • NEKTAR THERAPEUTICS Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2025 was $7,000.
  • NEKTAR THERAPEUTICS annual Net Cash Provided by (Used in) Financing Activities for 2025 was $180,566,000, a 329% increase from 2024.
  • NEKTAR THERAPEUTICS annual Net Cash Provided by (Used in) Financing Activities for 2024 was $42,118,000.
  • NEKTAR THERAPEUTICS annual Net Cash Provided by (Used in) Financing Activities for 2023 was $30,000.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)

NEKTAR THERAPEUTICS Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $180,566,000 +$138,448,000 +329% 01 Jan 2025 31 Dec 2025 10-K 13 Mar 2026 2025 FY
2024 $42,118,000 +$42,088,000 01 Jan 2024 31 Dec 2024 10-K 13 Mar 2026 2025 FY
2023 $30,000* -$1,478,000 01 Jan 2023 31 Dec 2023 10-K 14 Mar 2025 2024 FY
2022 $1,508,000 -$34,730,000 -96% 01 Jan 2022 31 Dec 2022 10-K 05 Mar 2024 2023 FY
2021 $36,238,000 +$116,592,000 01 Jan 2021 31 Dec 2021 10-K 05 Mar 2024 2023 FY
2020 $80,354,000 -$103,709,000 -444% 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
2019 $23,355,000 -$828,611,000 -97% 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
2018 $851,966,000 +$797,575,000 +1466% 01 Jan 2018 31 Dec 2018 10-K 26 Feb 2021 2020 FY
2017 $54,391,000 -$149,227,000 -73% 01 Jan 2017 31 Dec 2017 10-K 28 Feb 2020 2019 FY
2016 $203,618,000 01 Jan 2016 31 Dec 2016 10-K 01 Mar 2019 2018 FY
2013 $2,216,000 -$24,585,000 -92% 01 Jan 2013 31 Dec 2013 10-K 27 Feb 2014 2013 FY
2012 $26,801,000 -$195,534,000 -88% 01 Jan 2012 31 Dec 2012 10-K 27 Feb 2014 2013 FY
2011 $222,335,000 +$214,800,000 +2851% 01 Jan 2011 31 Dec 2011 10-K 27 Feb 2014 2013 FY
2010 $7,535,000 01 Jan 2010 31 Dec 2010 10-K 01 Mar 2013 2012 FY

NEKTAR THERAPEUTICS Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $7,000* -$41,996,000 01 Jan 2025 31 Mar 2025 10-Q 09 May 2025 2025 Q1
Q1 2024 $42,003,000 +$42,003,000 01 Jan 2024 31 Mar 2024 10-Q 09 May 2025 2025 Q1
Q1 2023 $0 -$938,000 -100% 01 Jan 2023 31 Mar 2023 10-Q 10 May 2024 2024 Q1
Q1 2022 $938,000 -$16,918,000 -95% 01 Jan 2022 31 Mar 2022 10-Q 10 May 2023 2023 Q1
Q1 2021 $17,856,000 +$6,779,000 +61% 01 Jan 2021 31 Mar 2021 10-Q 06 May 2022 2022 Q1
Q1 2020 $11,077,000 +$6,183,000 +126% 01 Jan 2020 31 Mar 2020 10-Q 07 May 2021 2021 Q1
Q1 2019 $4,894,000 -$29,458,000 -86% 01 Jan 2019 31 Mar 2019 10-Q 08 May 2020 2020 Q1
Q1 2018 $34,352,000 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019 2019 Q1
Q1 2013 $2,474,000 -$121,976,000 -102% 01 Jan 2013 31 Mar 2013 10-Q 09 May 2013 2013 Q1
Q1 2012 $119,502,000 -$101,997,000 -46% 01 Jan 2012 31 Mar 2012 10-Q 09 May 2013 2013 Q1
Q1 2011 $221,499,000 +$217,082,000 +4915% 01 Jan 2011 31 Mar 2011 10-Q 04 May 2012 2012 Q1
Q1 2010 $4,417,000 01 Jan 2010 31 Mar 2010 10-Q 29 Apr 2011 2011 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.